SCHERING-PLOUGH's INTRON A FOR CHRONIC HEPATITIS B RECEIVES ADVISORY COMMITTEE APPROVAL ENDORSEMENT; 42%-54% RESPONSE RATES SEEN IN CLINICAL TRIALS